Evidence map›Paper›PMID 35909563›Full record

ArticleFrontiers in endocrinology2022

Break-in Period ≤24 Hours as an Option for Urgent-start Peritoneal Dialysis in Patients With Diabetes.

Xiaoqing Hu, Liming Yang, Zhanshan Sun, Xiaoxuan Zhang, Xueyan Zhu, Wenhua Zhou, Xi Wen, Shichen Liu, Wenpeng Cui

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoqing HuDivision of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Liming YangDivision of Nephrology, The First Hospital of Jilin University-the Eastern Division, Changchun, China.
Zhanshan SunDivision of Nephrology, Xing'anmeng people's Hospital, Inner Mongolia, China.
Xiaoxuan ZhangDivision of Nephrology, Jilin FAW General Hospital, Changchun, China.
Xueyan ZhuDivision of Nephrology, Jilin City Central Hospital, Jilin, China.
Wenhua ZhouDivision of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Xi WenDivision of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Shichen LiuDivision of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Wenpeng CuiDivision of Nephrology, The Second Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal break-in period (BI) of urgent-start peritoneal dialysis (USPD) initiation for patients with end-stage renal disease (ESRD) and diabetes is unclear. We aimed to explore the safety and applicability of a BI ≤24 h in patients with ESRD and diabetes. Methods: We used a retrospective cohort design wherein we recruited patients with ESRD and diabetes who underwent USPD at five institutions in China between January 2013 and August 2020. The enrolled patients were grouped according to BI. The primary outcomes were mechanical and infectious complication occurrences, whereas the secondary outcome was technique survival. Results: We enrolled 310 patients with diabetes, of whom 155 and 155 patients were in the BI ≤24 h and BI >24 h groups, respectively. The two groups showed a comparable incidence of infectious and mechanical complications within 6 months after catheter insertion ( Conclusion: USPD initiation with a BI ≤24 h may be safe and feasible for patients with ESRD and diabetes.

Indexed as

Diabetes MellitusKidney Failure, ChronicPeritoneal DialysisHumansRetrospective StudiesTime Factorsbreak-in periodcomplicationsdiabeticsend-stage renal diseaseurgent start peritoneal dialysis

Identifiers

PMID35909563
PMCPMC9329536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.